Close Menu

Myriad

Myriad Genetics' shareholders received shares in the pharma spin off. The firm also said it had retained the rights to claim $400 million in tax deductions.

The Salt Lake City-based firm said that it expects to report fourth-quarter molecular diagnostic revenues of $86 million. Analysts, on average, were expecting revenues of $91.6 million for the quarter ended June 30.

People In The News

Compugen Named co-CEOs this week, while Rules-Based Medicine hired a new VP of clinical diagnostics, and an Affymetrix director decided to step down.

Myriad Genetics' shareholders of record on June 17 will receive on June 30 a pro-rata dividend of .25 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics held.

The two-for-one split of the firm's shares took place before the opening of the market today.

The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.

The firm's two-for-one stock split will cut the number of shares it will distribute to current shareholders in Myriad Pharmaceuticals.

On its website, the company informs customers that its service tests for the i4000377, i4000378, and i4000379 SNPs in BRCA1 and BRCA2 genes, either one of which may “influence your carrier status for breast/ovarian cancer.”

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.